^
Association details:
| Biomarker: | EGFR exon 18 deletion |
|---|---|
| Cancer: | Lung Adenocarcinoma |
| Drug: | Gilotrif (afatinib) (EGFR inhibitor, HER2 inhibitor, HER4 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
EGFR Exon 18 Mutations in Lung Cancer: Molecular Predictors of Augmented Sensitivity to Afatinib or Neratinib as Compared with First- or Third-Generation TKIs
Excerpt:
After that, direct sequencing of the RNA extracted from cells in pleural effusion revealed EGFR Del18 (delE709_T710insD) mutation (Fig. 5A). Although it was unknown whether this mutation was sensitive, erlotinib 150 mg was started. Serious rashes on the legs forced us to cease treatment with erlotinib, which achieved stable disease. After switching to afatinib 40 mg, substantial tumor shrinkage was noted (Fig. 5B).
DOI:
10.1158/1078-0432.CCR-15-1046
